Innoviva (INVA) Stock Price, News & Analysis

Company Overview

Innoviva, Inc. is a healthcare company focused on developing, commercializing and managing medicines, with an emphasis on respiratory and hospital-based therapies. The company’s business model includes royalty interests in marketed products as well as ownership and investment in companies developing or commercializing innovative treatments.

Innoviva receives royalty revenue from respiratory medicines developed in collaboration with GlaxoSmithKline, including Trelegy Ellipta, Anoro Ellipta and Relvar/Breo Ellipta. These products are used to treat conditions such as chronic obstructive pulmonary disease and asthma and are marketed in the United States and international markets.

Through its specialty pharmaceutical activities, including Innoviva Specialty Therapeutics, the company has also been involved in commercializing hospital medicines such as XERAVA (eravacycline), an antibiotic for complicated intra-abdominal infections, and GIAPREZA (angiotensin II), a treatment for certain forms of distributive shock. Innoviva also has exposure to biotechnology programs through investments and subsidiaries, including Armata Pharmaceuticals, which is developing bacteriophage-based therapies.

The company was formerly known as Theravance, Inc. and adopted the Innoviva name following the separation of its biopharmaceutical operations into Theravance Biopharma. Innoviva is headquartered in the San Francisco Bay Area and works with pharmaceutical partners and healthcare providers across the United States and international markets.

Key Stats

• Today's Range: $20.51 to $20.94
• 50-Day Range: $20.24 to $21.48
• 52-Week Range: $17.45 to $25.15
• Volume: 978,551 shs
• Average Volume: 674,364 shs
• Market Capitalization: $1.49 billion
• P/E Ratio: 5.04
• Dividend Yield: N/A
• Price Target: $39.25
• Consensus Rating: Moderate Buy

Innoviva Stock Analysis - MarketRank™

Innoviva scored higher than 72% of companies evaluated by MarketBeat, and ranked 193rd out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Innoviva has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Innoviva has a consensus price target of $39.25, representing about 90.0% upside from its current price of $20.66.

Amount of Analyst Coverage

Innoviva has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -7.79%

Earnings Growth

Earnings for Innoviva are expected to decrease by -7.79% in the coming year, from $2.31 to $2.13 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Innoviva is 5.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of Innoviva is 5.04, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.87.

Price to Earnings Growth Ratio

Innoviva has a PEG Ratio of 3.04. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Innoviva has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.67% of the float of Innoviva has been sold short.

Short Interest Ratio / Days to Cover

Innoviva has a short interest ratio ("days to cover") of 5.66.

Change versus previous month

Short interest in Innoviva has recently decreased by 4.18%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Innoviva does not currently pay a dividend.

Dividend Growth

Innoviva does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.86

News Sentiment

Innoviva has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Innoviva this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for INVA on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Innoviva to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Innoviva insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.01% of the stock of Innoviva is held by insiders.

Percentage Held by Institutions

99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 10/24/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:INVA
• Previous Symbol: NASDAQ:THRX
• CIK: 1080014
• Web: www.inva.com
• Phone: (650) 238-9600
• Fax: 650-827-8690
• Employees: 159
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Innoviva: $39.25
• High Price Target: $46.00
• Low Price Target: $34.00
• Potential Upside/Downside: +90.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.10
• Trailing P/E Ratio: 5.04
• Forward P/E Ratio: 8.94
• P/E Growth: 3.04
• Net Income: $271.17 million
• Net Margins: 81.19%
• Pretax Margin: 95.32%
• Return on Equity: 28.03%
• Return on Assets: 20.19%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 16.01
• Quick Ratio: 15.18

Sales & Book Value

• Annual Sales: $411.33 million
• Price / Sales: 3.63
• Cash Flow: $4.93 per share
• Price / Cash Flow: 4.19
• Book Value: $15.71 per share
• Price / Book: 1.32

Miscellaneous

• Outstanding Shares: 72,250,000
• Free Float: 70,793,000
• Market Cap: $1.49 billion
• Optionable: Optionable
• Beta: 0.38